Policy development for Clostridium difficile
نویسندگان
چکیده
منابع مشابه
Policy development for Clostridium difficile.
The Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) was created at the height of the incidence of Clostridium difficile infection (CDI). This article describes the role of ARHAI in the evaluation of laboratory testing for CDI, a related consultation on the legal requirements for manufacturers of in vitro diagnostic medical devices, a CDI healthcare bun...
متن کاملclostridium difficile
seventy-five meconium samples were examined for the presence of ci. difficile: 3 strains were isola ted. additionally 45 labora tory animal faeces specimens were tested for the same purpose, a further 2 cases were isolated. these five suspicious strains were identified as ci. difficile acco rding to the tests mentioned in the previous paragraphs. the organisms . isolated here showed the same ch...
متن کاملDevelopment of a sporicidal test method for Clostridium difficile.
BACKGROUND Disinfectants with claimed activity against Clostridium difficile must be evaluated to ensure efficacy against the spores that comprise an environmental source of patient infection. Unfortunately there is, at present, no generally accepted method for evaluating these disinfectants. In the absence of such a method, laboratories have to adapt protocols that were not designed for produc...
متن کاملDevelopment of Photodynamic Antimicrobial Chemotherapy (PACT) for Clostridium difficile
BACKGROUND Clostridium difficile is the leading cause of antibiotic-associated diarrhoea and pseudo membranous colitis in the developed world. The aim of this study was to explore whether Photodynamic Antimicrobial Chemotherapy (PACT) could be used as a novel approach to treating C. difficile infections. METHODS PACT utilises the ability of light-activated photosensitisers (PS) to produce rea...
متن کاملFidaxomicin for Clostridium difficile Infection.
To the Editor: In their randomized study comparing fidaxomicin with vancomycin for Clostridium difficile infection, Louie et al. (Feb. 3 issue)1 found that substantially fewer patients in the fidaxomicin group had recurrences of C. difficile infection within 4 weeks after the conclusion of treatment. We recently reported on an observational study involving U.S. veterans in which the recurrence ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Antimicrobial Chemotherapy
سال: 2012
ISSN: 0305-7453,1460-2091
DOI: 10.1093/jac/dks203